Does Stensiq Elevate Alkaline Phosphatase?
Yes, Stensiq (asfotase alfa) causes markedly elevated serum alkaline phosphatase (ALP) levels, but these elevations are expected and reflect the circulating drug itself, not liver or bone pathology. 1
Mechanism of Elevation
Stensiq is a recombinant tissue-nonspecific alkaline phosphatase enzyme replacement therapy. When administered, the drug circulates in the bloodstream and is directly measured by standard ALP laboratory assays. The FDA label explicitly states: "High serum ALP measurements detected through clinical laboratory testing are expected in patients receiving STRENSIQ and reflect circulating concentrations of asfotase alfa." 1
Critical Clinical Implications
Do Not Use ALP for Clinical Decision-Making
The FDA label provides a clear directive: "Do not rely on serum ALP measurements for clinical decision making in patients treated with STRENSIQ." 1 This is crucial because:
- The elevated ALP does NOT indicate liver disease, bone disease, or cholestasis
- The elevation is pharmacologic, not pathologic
- Standard diagnostic algorithms for elevated ALP (as outlined in guidelines 2, 3) do not apply to patients on Stensiq
Laboratory Test Interference
Beyond direct ALP measurement, Stensiq causes analytical interference with any laboratory test that uses an ALP-conjugated detection system. These tests measure various substances including hormones, bacterial antigens, and antibodies. To avoid erroneous results, inform laboratory personnel that the patient is receiving Stensiq and request testing platforms that do not utilize ALP-conjugate technology. 1
Clinical Context: What Stensiq Actually Does
Patients with hypophosphatasia have pathologically LOW alkaline phosphatase due to ALPL gene mutations. Treatment with asfotase alfa:
- Increases ALP levels (as the drug IS alkaline phosphatase) 4
- Decreases pyridoxal 5'-phosphate (PLP) and inorganic pyrophosphate (PPi) levels 4
- Improves bone mineralization, survival, respiratory function, and quality of life 4, 5
The therapeutic goal is enzyme replacement, so elevated ALP during treatment indicates drug presence, not treatment failure or adverse effect.
Common Pitfall to Avoid
Do not misinterpret elevated ALP in a Stensiq-treated patient as cholestatic liver disease or bone pathology. While guidelines 2, 3 appropriately recommend investigating elevated ALP for biliary obstruction, primary biliary cholangitis, or bone disease in the general population, these algorithms are invalidated in patients receiving asfotase alfa. If liver or bone disease is suspected clinically, use alternative biomarkers and imaging rather than ALP levels.